Pemakaian Nikotinamide Dalam Penanganan Hiperfosfatemia Pada Pasien Hemodialisis
51
LAMPIRAN 1
Universitas Sumatera Utara
52
LAMPIRAN 2
LEMBARAN PENJELASAN
Assalamualaikum wr.wb,
Salam sejahtera bagi Bapak/Ibu,
Terima kasih atas kesediaan Bapak/Ibu meluangkan waktu untuk
membaca dan mengisi surat persetujuan ini, sebelumnya, perkenankan saya
memperkenalkan diri. Nama saya dr. Meivina Ramadhani Pane, Peserta Program
Pendidikan Dokter Spesialis Ilmu Penyakit Dalam di Fakultas Kedokteran
Universitas Sumatera Utara (FK-USU). Saya sedang melakukan pengumpulan
data penelitian tugas akhir sebagai salah satu syarat menyelesaikan pendidikan di
FK-USU. Adapun judul penelitian saya adalah ―Efikasi dan keamanan
nikotinamide dalam penanganan hiperfosfatemia pada pasien hemodialisis‖
Penelitian ini bertujuan untuk mengetahui efektivitas dan keamanan
penggunaan Nikotinamide dalam menurunkan kadar fosfat darah pada pasien cuci
darah dengan harga yang relatif lebih murah dibandingkan dengan obat yang
sudah ada sebelumnya di pasaran.
Penelitian ini dimulai dengan pengambilan sampel darah vena sebanyak ±
2 sendok makan yang dilakukan sebelum hemodialisis dimulai. Sampel darah ini
digunakan untuk pemeriksaan darah rutin, LFT, RFT, fosfat, kalsium, albumin,
dan profil lipid. Kemudian apabila kadar serum fosfat pasien ≥ 5.5 mg/dl, maka
akan diberikan kapsul nikotinamide 250 mg 2 kali sehari pada pagi dan petang
hari pada saat makan. Kemudian setelah 4 minggu dan 8 minggu dilakukan
pengambilan darah kembali untuk menilai darah rutin, fosfat, kalsium, fungsi hati,
fungsi ginjal dan profil lipid.
Universitas Sumatera Utara
53
Penelitian ini tidak berbahaya, pada saat pengambilan darah dapat timbul
lebam pada bekas tempat pengambilan yang akan hilang sendiri dalam satu atau
dua hari. Sementara nikotinamide berdasarkan pengalaman selama ini belum
pernah menunjukkan bahaya yang serius. Beberapa efek samping yang mungkin
terjadi dari pemberian obat ini adalah diare, penurunan kadar trombosit dan
kemerahan pada wajah. Namun efek samping tersebut akan hilang jika dosis obat
dikurangi. Efek samping obat tersebut biasanya terjadi jika diberikan dengan dosis
tinggi, sedangkan pada penelitian ini dosis obat yang diberikan adalah 500 mg per
hari. Segala biaya pemeriksaan laboratorium, penyediaan obat dan biaya
penanganan yang diperlukan bila timbul efek samping akan menjadi tanggung
jawab peneliti.
Terimakasih atas keikutsertaan Bapak/Ibu. Apabila ada hal-hal yang
terjadi selama penelitian dan ada keterangan yang saya berikan masih belum jelas
atau yang ingin ditanyakan, Bapak/Ibu dapat menghubungi saya :
Nama
: dr. Meivina Ramadhani Pane
Alamat
: Jl. Suka Ramai No.4 Medan
No Telp
: 081260297727
Atas perhatian Bapak/Ibu saya ucapkan terima kasih.
Hormat saya,
dr. Meivina Ramadhani Pane
Universitas Sumatera Utara
54
LAMPIRAN 3
LEMBAR PERSETUJUAN SETELAH PENJELASAN
(INFORMED CONSENT)
=======================================================
No. Peserta :
Saya yang bertanda tangan di bawah ini :
Nama
:
Umur
:
Jenis Kelamin
: Laki-laki / Perempuan *
Alamat
:
No. Telepon
:
tahun
Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan
prosedur penelitian ini, menyatakan bersedia untuk ikut dalam penelitian tentang :
―EFIKASI DAN KEAMANAN NIKOTINAMIDE DALAM PENANGANAN
HIPERFOSFATEMIA PADA PASIEN HEMODIALISIS‖.
Demikian surat pernyataan bersedia ikut dalam penelitian ini saya perbuat
untuk dapat digunakan seperlunya.
Medan,
2013
Peneliti,
Pasien,
( dr. Meivina Ramadhani Pane )
(.......................................)
Saksi,
(................................)
Universitas Sumatera Utara
55
LAMPIRAN 4
KERTAS KERJA PROFIL PESERTA PENELITIAN
I. IDENTITAS PRIBADI
Nama
:
Umur
:
Jenis Kelamin
: pria/wanita
Riwayat penyakit
: DM/hipertensi/batu ginjal/kista
HD sejak
:
tahun
II. HASIL PEMERIKSAAN LABORATORIUM
Parameter
Sebelum
Minggu ke-4
Minggu Ke-8
Fosfat (mg/dl)
Kalsium (mg/dl)
Fosfat x kalsium
(mg2/dl2)
Trombosit (x103/mm3)
SGOT (U/L)
SGPT (U/L)
HDL (mg/dl)
LDL (mg/dl)
III. EFEK SAMPING YANG TIMBUL (sebutkan)
.................................
Universitas Sumatera Utara
56
LAMPIRAN 5
Data Penelitian Sebelum Pemberian Nikotinamide
Pasien
Umur
(THN)
JK
Fosfat
(mg/dl)
Kalsium
(mg/dl)
CaxP
(mg2/dl2)
Trombosit
(103/mm3)
SGOT
(U/L)
SGPT
(U/L)
HDL
(mg/dl)
LDL
(mg/dl)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
54
55
38
70
40
53
43
46
41
59
43
35
38
44
42
32
54
P
P
L
L
L
L
L
L
L
L
L
L
L
L
P
L
P
7
7
7.2
6.3
7.9
6.3
11.3
8.1
9.2
9.5
9.5
9
7.3
9.9
7.4
9.5
6.2
9.2
10.3
8.6
9.8
9.1
9.9
9
9.6
10.3
9.6
10.3
10
10.6
9.1
8.8
9.3
11.5
64.4
72.1
61.9
61.74
71.89
62.37
101.7
77.76
94.76
91.2
97.85
90
77.38
90.09
65.12
88.35
71.3
179
186
147
160
340
157
130
123
213
284
331
173
263
167
230
165
237
23
31
45
51
23
34
20
18
65
71
16
34
19
18
31
37
41
22
45
16
37
15
49
50
13
11
45
10
43
14
17
29
48
51
43
38
33
35
23
34
37
38
33
50
49
37
64
56
54
28
49
131
83
64
101
123
99
60
138
113
99
99
78
143
110
109
88
69
Data Penelitian Setelah Minggu ke-4 Pemberian Nikotinamide
Pasien
Umur
(THN)
JK
Fosfat
(mg/dl)
Kalsium
(mg/dl)
CaxP
(mg2/dl2)
Trombosit
(103/mm3)
SGOT
(U/L)
SGPT
(U/L)
HDL
(mg/dl)
LDL
(mg/dl)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
54
55
38
70
40
53
43
46
41
59
43
35
38
44
42
32
54
P
P
L
L
L
L
L
L
L
L
L
L
L
L
P
L
P
9.7
8
5.5
5.7
8
5.7
10.6
7.6
8.3
6.6
8.1
5.6
7
10.2
6.5
9.3
5.8
8.6
10.6
8.7
9.8
8.4
8.2
7.5
8.8
10
9
10.2
8.6
10.7
8.9
8.3
8.2
10.7
83.42
84.8
47.85
55.86
67.2
46.74
79.5
66.88
83
59.4
82.62
48.16
74.9
90.78
53.95
76.26
62.06
146
221
172
165
228
166
125
129
198
246
243
170
283
195
200
282
215
28
23
23
38
22
18
44
12
20
33
20
35
19
17
32
45
27
20
41
40
35
25
30
63
22
17
35
13
44
13
17
35
55
23
41
41
34
37
27
25
44
35
38
44
35
38
53
56
20
38
27
123
68
77
98
149
105
63
112
116
110
70
81
98
104
97
90
86
Universitas Sumatera Utara
57
Data Penelitian Setelah Minggu ke-8 Pemberian Nikotinamide
Pasien
Umur
(THN)
JK
Fosfat
(mg/dl)
Kalsium
(mg/dl)
CaxP
(mg2/dl2)
Trombosit
(103/mm3)
SGOT
(U/L)
SGPT
(U/L)
HDL
(mg/dl)
LDL
(mg/dl)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
54
55
38
70
40
53
43
46
41
59
43
35
38
44
42
32
54
P
P
L
L
L
L
L
L
L
L
L
L
L
L
P
L
P
7.8
7.9
5.2
3.4
6.9
5.1
9.6
5.3
7.2
5.1
8.5
5.5
7.9
9.9
6.3
9.1
2.7
8.2
10.9
8.8
9.6
8.7
8.5
8.8
8.6
10
8.7
9.7
8.3
10
8.2
8.5
9.1
11.7
63.96
86.11
45.76
32.64
60.03
43.35
84.48
45.58
72
44.37
82.45
45.65
70
81.18
53.55
82.81
31.59
258
251
165
160
348
170
167
159
189
230
252
161
287
158
232
249
155
34
21
22
28
20
20
12
13
16
30
18
34
19
27
32
23
35
23
31
35
21
23
28
19
20
10
40
10
37
13
55
33
29
27
41
39
35
41
30
30
42
40
45
48
30
37
37
76
39
26
35
120
64
78
95
139
97
76
125
110
125
75
75
124
103
146
79
77
Keterangan:
P : Perempuan
L : Laki-laki
Universitas Sumatera Utara
58
LAMPIRAN 6
OUTPUT ANALISIS
Jk
Valid
L
P
Total
Frequency
13
4
Percent
76,5
23,5
Valid Percent
76,5
23,5
17
100,0
100,0
Cumulative
Percent
76,5
100,0
Penyebab
Valid
Batu ginjal
DM
DN
GNC
HN
Total
Umur
Lama HD (tahun)
Ca1
Ca2
Ca3
Fosfat1
Fosfat2
Fosfat3
CaxFosfat1
CaxFosfat2
CaxFosfat3
Trombosit1
Trombosit2
Trombosit3
SGOT1
SGOT2
SGOT3
SGPT1
SGPT2
SGPT3
HDL1
HDL2
HDL3
LDL1
LDL2
LDL3
Frequency
1
1
3
1
11
Percent
5,9
5,9
17,6
5,9
64,7
Valid Percent
5,9
5,9
17,6
5,9
64,7
17
100,0
100,0
Cumulative
Percent
5,9
11,8
29,4
35,3
100,0
Case Processing Summary
Cases
Valid
Missing
N
Percent
N
Percent
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
Total
N
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
Percent
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
Universitas Sumatera Utara
59
Descriptives
Umur
Mean
95% Confidence Interval for
Mean
Statistic
46,2941
Lower Bound
41,2409
Upper Bound
51,3474
5% Trimmed Mean
45,7712
Median
43,0000
Variance
96,596
Std. Deviation
Lama HD (tahun)
9,82831
Minimum
32,00
Maximum
70,00
Range
38,00
Interquartile Range
15,00
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
,835
,512
4,2453
2,9773
Upper Bound
5,5133
5% Trimmed Mean
4,1798
Median
4,0000
Variance
2,46622
Minimum
,67
Maximum
9,00
Range
8,33
Interquartile Range
Ca1
Lower Bound
4,25
,448
-,760
9,7059
9,3218
Upper Bound
10,0900
5% Trimmed Mean
9,6676
Median
9,6000
Variance
,74705
Minimum
8,60
Maximum
11,50
Range
2,90
Interquartile Range
Ca2
,550
1,063
,18119
,558
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
,59815
6,082
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Std. Error
2,38371
Lower Bound
1,20
,690
,484
9,1294
8,6157
Upper Bound
9,6432
5% Trimmed Mean
9,1327
Median
8,8000
,550
1,063
,24235
Universitas Sumatera Utara
60
Variance
,998
Std. Deviation
,99923
Minimum
7,50
Maximum
10,70
Range
3,20
Interquartile Range
Ca3
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
1,75
,412
-1,059
9,1941
8,6830
Upper Bound
9,7052
5% Trimmed Mean
9,1101
Median
8,8000
Variance
,988
Std. Deviation
,99403
Minimum
8,20
Maximum
11,70
Range
3,50
Interquartile Range
Fosfat1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
1,35
1,300
1,211
8,1529
7,3836
Upper Bound
8,9223
5% Trimmed Mean
8,0866
Median
7,9000
Variance
1,49629
Minimum
6,20
Maximum
11,30
Range
5,10
Interquartile Range
Fosfat2
Lower Bound
2,50
,432
-,708
7,5412
6,6741
Upper Bound
8,4082
5% Trimmed Mean
7,4846
Median
7,6000
Variance
1,68636
Minimum
5,50
Maximum
10,60
Range
5,10
Interquartile Range
Fosfat3
,550
1,063
,40900
2,844
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
,550
1,063
,36290
2,239
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
,24109
Lower Bound
3,05
,414
-1,010
6,6706
5,5964
,550
1,063
,50670
Universitas Sumatera Utara
61
Mean
Upper Bound
6,7118
Median
6,9000
Variance
4,365
Std. Deviation
2,08919
Minimum
2,70
Maximum
9,90
Range
7,20
Interquartile Range
CaxFosfat1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
3,05
-,219
-,693
78,8182
71,7393
Upper Bound
85,8972
5% Trimmed Mean
78,4958
Median
77,3800
Variance
13,76813
Minimum
61,74
Maximum
101,70
Range
39,96
Interquartile Range
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
25,89
,207
-1,479
68,4341
60,9060
Upper Bound
75,9622
5% Trimmed Mean
68,3979
Median
67,2000
Variance
214,383
Std. Deviation
46,74
Maximum
90,78
Range
44,04
Interquartile Range
CaxFosfat3
Lower Bound
27,91
-,143
-1,428
60,3241
50,5796
Upper Bound
70,0687
5% Trimmed Mean
60,4879
Median
60,0300
Variance
Std. Deviation
,550
1,063
3,55116
14,64183
Minimum
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
3,33926
189,561
Std. Deviation
CaxFosfat2
7,7447
5% Trimmed Mean
,550
1,063
4,59669
359,203
18,95265
Minimum
31,59
Maximum
86,11
Range
54,52
Interquartile Range
36,84
Universitas Sumatera Utara
62
Trombosit1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
,015
-1,503
205,00
170,85
Upper Bound
239,15
5% Trimmed Mean
202,06
Median
179,00
Variance
4410,375
Std. Deviation
66,411
Minimum
123
Maximum
340
Range
217
Interquartile Range
Trombosit2
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
92
,883
-,194
199,06
174,44
Upper Bound
223,68
5% Trimmed Mean
198,51
Median
198,00
Variance
47,886
Minimum
125
Maximum
283
Range
158
Interquartile Range
Trombosit3
Lower Bound
70
,238
-,670
211,24
181,85
Upper Bound
240,62
5% Trimmed Mean
189,00
Variance
3265,441
Std. Deviation
57,144
Minimum
155
Maximum
348
Range
193
Interquartile Range
SGOT1
Lower Bound
91
,872
,148
33,94
25,50
Upper Bound
42,38
5% Trimmed Mean
32,88
Median
31,00
Variance
Std. Deviation
Minimum
,550
1,063
13,859
206,76
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
11,614
2293,059
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
16,107
,550
1,063
3,983
269,684
16,422
16
Universitas Sumatera Utara
63
Maximum
71
Range
55
Interquartile Range
SGOT2
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
24
1,039
,435
26,82
21,87
Upper Bound
31,78
5% Trimmed Mean
26,64
Median
23,00
Variance
92,779
Std. Deviation
9,632
Minimum
12
Maximum
45
Range
33
Interquartile Range
SGOT3
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
15
,568
-,577
23,76
19,95
Upper Bound
27,58
5% Trimmed Mean
23,79
Median
22,00
Variance
7,421
Minimum
12
Maximum
35
Range
23
Interquartile Range
SGPT1
Lower Bound
13
,121
-1,172
30,29
22,01
Upper Bound
38,58
5% Trimmed Mean
29,00
Variance
259,596
Std. Deviation
16,112
Minimum
10
Maximum
51
Range
41
Interquartile Range
SGPT2
,550
1,063
3,908
30,27
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
1,800
55,066
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
2,336
Lower Bound
32
,049
-1,931
31,06
23,63
Upper Bound
38,49
5% Trimmed Mean
30,29
Median
30,00
,550
1,063
3,505
Universitas Sumatera Utara
64
Variance
208,809
Std. Deviation
14,450
Minimum
13
Maximum
63
Range
50
Interquartile Range
SGPT3
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
22
,708
-,039
26,71
20,78
Upper Bound
32,63
5% Trimmed Mean
26,06
Median
27,00
Variance
132,971
Std. Deviation
11,531
Minimum
10
Maximum
55
Range
45
Interquartile Range
HDL1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
15
,649
,917
41,24
35,65
Upper Bound
46,82
5% Trimmed Mean
38,00
Variance
118,191
Std. Deviation
10,872
Minimum
23
Maximum
64
Range
41
Interquartile Range
HDL2
Lower Bound
16
,461
-,323
37,24
32,43
Upper Bound
42,04
5% Trimmed Mean
37,15
Median
38,00
Variance
9,351
Minimum
20
Maximum
56
Range
36
Interquartile Range
HDL3
,550
1,063
2,268
87,441
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
,550
1,063
2,637
40,98
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
2,797
Lower Bound
12
,182
,191
39,47
33,79
,550
1,063
2,679
Universitas Sumatera Utara
65
Mean
Upper Bound
38,19
Median
39,00
Variance
122,015
Std. Deviation
11,046
Minimum
26
Maximum
76
Range
50
Interquartile Range
LDL1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
9
2,331
7,628
100,41
87,62
Upper Bound
113,21
5% Trimmed Mean
99,00
Variance
619,257
Std. Deviation
24,885
Minimum
60
Maximum
143
Range
83
Interquartile Range
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
38
,047
-,753
96,88
85,53
Upper Bound
108,24
5% Trimmed Mean
98,00
Variance
487,610
Std. Deviation
22,082
Minimum
63
Maximum
149
Range
86
Interquartile Range
LDL3
32
,507
,494
100,47
Lower Bound
87,25
Upper Bound
113,69
5% Trimmed Mean
99,97
Median
97,00
Variance
Std. Deviation
,550
1,063
6,236
661,140
25,713
Minimum
64
Maximum
146
Range
,550
1,063
5,356
95,87
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
6,035
100,29
Median
LDL2
45,15
5% Trimmed Mean
82
Universitas Sumatera Utara
66
Interquartile Range
48
Skewness
Kurtosis
,299
-1,276
Tests of Normality
Kolmogorov-Smirnova
Statistic
df
Sig.
Umur
,181
17
,144
Lama HD (tahun)
,164
17
,200*
Ca1
,118
17
,200*
Ca2
,199
17
,073
Ca3
,242
17
,009
Fosfat1
,163
17
,200*
Fosfat2
,143
17
,200*
Fosfat3
,124
17
,200*
CaxFosfat1
,167
17
,200*
CaxFosfat2
,141
17
,200*
CaxFosfat3
,191
17
,101
Trombosit1
,201
17
,067
Trombosit2
,126
17
,200*
Trombosit3
,235
17
,013
SGOT1
,159
17
,200*
SGOT2
,184
17
,130
SGOT3
,129
17
,200*
SGPT1
,207
17
,051
SGPT2
,133
17
,200*
SGPT3
,097
17
,200*
HDL1
,205
17
,055
HDL2
,129
17
,200*
HDL3
,233
17
,015
LDL1
,124
17
,200*
LDL2
,090
17
,200*
LDL3
,210
17
,045
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Statistic
,935
,953
,955
,908
,856
,930
,919
,962
,907
,925
,905
,901
,962
,856
,888
,941
,941
,845
,937
,958
,958
,964
,771
,968
,969
,917
Shapiro-Wilk
df
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
,550
1,063
Sig.
,268
,503
,549
,091
,013
,220
,142
,674
,089
,179
,083
,072
,673
,013
,044
,335
,332
,009
,279
,600
,588
,715
,001
,787
,798
,131
Wilcoxon Signed Ranks Test
Ranks
N
Ca2 - Ca1
Ca3 - Ca1
Negative Ranks
Positive Ranks
Ties
13a
3b
Total
17
14d
3e
0f
Negative Ranks
Positive Ranks
Ties
Total
Ca3 - Ca2
Negative Ranks
Positive Ranks
Ties
Total
a. Ca2 < Ca1
b. Ca2 > Ca1
c. Ca2 = Ca1
d. Ca3 < Ca1
Mean Rank
9,73
3,17
Sum of Ranks
126,50
9,50
9,79
5,33
137,00
16,00
8,25
8,75
66,00
70,00
c
1
17
8g
8h
1i
17
e. Ca3 > Ca1
f. Ca3 = Ca1
g. Ca3 < Ca2
h. Ca3 > Ca2
Universitas Sumatera Utara
67
i. Ca3 = Ca2
Test Statistics
Ca2 - Ca1
Z
-3,029b
Asymp. Sig. (2-tailed)
,002
a. Wilcoxon Signed Ranks Test
b. Based on positive ranks.
c. Based on negative ranks.
a
Ca3 - Ca1
-2,875b
,004
Ca3 - Ca2
-,104c
,917
Friedman Test
Ranks
Mean Rank
Fosfat sebelum pemberian
Niacinamide, mg/dl
Fosfat setelah pemberian
Niacinamide 4 minggu,
mg/dl
Fosfat setelah pemberian
Niacinamide 8 minggu,
mg/dl
2,56
2,12
1,32
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
13,522
2
,001
General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
Fosfat
Dependent Variable
1
Fosfat1
2
Fosfat2
3
Fosfat3
a
Effect
Fosfat
Pillai's Trace
Wilks' Lambda
Hotelling's Trace
Roy's Largest Root
a. Design: Intercept
Within Subjects Design: Fosfat
b. Exact statistic
Multivariate Tests
Value
F
Hypothesis df
,521
8,142b
2,000
,479
8,142b
2,000
1,086
8,142b
2,000
1,086
8,142b
2,000
Error df
15,000
15,000
15,000
15,000
Sig.
,004
,004
,004
,004
Universitas Sumatera Utara
68
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Epsilonb
Within
Subjects
Approx. ChiGreenhouseEffect
Mauchly's W
Square
df Sig.
Geisser
Huynh-Feldt
Lower-bound
Fosfat
,814
3,093
2 ,213
,843
,931
,500
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent
variables is proportional to an identity matrix.
a. Design: Intercept
Within Subjects Design: Fosfat
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are
displayed in the Tests of Within-Subjects Effects table.
Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
Fosfat
Error(Fosfat)
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Type III Sum of
Squares
18,867
18,867
18,867
18,867
29,559
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
df
2
1,686
1,863
1,000
32
Mean Square
9,434
11,191
10,130
18,867
,924
29,559
26,974
1,096
29,559
29,800
,992
29,559
16,000
1,847
F
10,213
10,213
10,213
10,213
Tests of Within-Subjects Contrasts
Measure: MEASURE_1
Source
Fosfat
Error(Fosfat)
Fosfat
Linear
Quadratic
Linear
Type III Sum of
Squares
18,678
,190
20,132
Quadratic
9,427
df
1
1
16
Mean Square
18,678
,190
1,258
16
,589
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
Df
Mean Square
Intercept
2834,354
1
2834,354
Error
121,600
16
7,600
F
372,942
F
14,844
,322
Sig.
,001
,578
Sig.
,000
Universitas Sumatera Utara
Sig.
,00
,00
,00
,00
69
Estimated Marginal Means
Fosfat
Estimates
Measure: MEASURE_1
Fosfat
1
2
3
Mean
8,153
7,541
6,671
95% Confidence Interval
Lower Bound
Upper Bound
7,384
8,922
6,674
8,408
5,596
7,745
Std. Error
,363
,409
,507
Pairwise Comparisons
Measure: MEASURE_1
Mean Difference
(I) Fosfat
(J) Fosfat
(I-J)
Std. Error
1
2
,612
,333
3
1,482*
,385
2
1
-,612
,333
*
3
,871
,259
3
1
-1,482*
,385
*
2
-,871
,259
Based on estimated marginal means
*. The mean difference is significant at the ,05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Sig.b
,255
,004
,255
,012
,004
,012
95% Confidence Interval for
Differenceb
Lower Bound
Upper Bound
-,279
1,503
,454
2,511
-1,503
,279
,179
1,562
-2,511
-,454
-1,562
-,179
Multivariate Tests
Value
F
Hypothesis df
Error df
Pillai's trace
,521
8,142a
2,000
15,000
Wilks' lambda
,479
8,142a
2,000
15,000
Hotelling's trace
1,086
8,142a
2,000
15,000
Roy's largest root
1,086
8,142a
2,000
15,000
Each F tests the multivariate effect of Fosfat. These tests are based on the linearly
independent pairwise comparisons among the estimated marginal means.
a. Exact statistic
Sig.
,004
,004
,004
,004
General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
Dependent
KalsiumxFosfat
Variable
1
CaxFosfat1
2
CaxFosfat2
3
CaxFosfat3
Effect
KalsiumxFosfat
Pillai's Trace
Wilks' Lambda
Hotelling's Trace
Roy's Largest Root
Multivariate Testsa
Value
F
,596
11,069b
,404
11,069b
1,476
11,069b
1,476
11,069b
Hypothesis df
2,000
2,000
2,000
2,000
Error df
15,000
15,000
15,000
15,000
a. Design: Intercept
Within Subjects Design: KalsiumxFosfat
Universitas Sumatera Utara
Sig.
,001
,001
,001
,001
70
b. Exact statistic
Mauchly's Test of Sphericity
a
Measure: MEASURE_1
Epsilonb
Within Subjects
Approx. ChiGreenhouseEffect
Mauchly's W
Square
df Sig.
Geisser
Huynh-Feldt
Lower-bound
KalsiumxFosfat
,803
3,300
2 ,192
,835
,921
,500
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables
is proportional to an identity matrix.
a. Design: Intercept
Within Subjects Design: KalsiumxFosfat
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are
displayed in the Tests of Within-Subjects Effects table.
Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
KalsiumxFosfat
Error(KalsiumxFosfat)
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Type III Sum of
Squares
2921,928
2921,928
2921,928
2921,928
3065,571
2
1,670
1,842
1,000
32
Mean Square
1460,964
1749,487
1586,448
2921,928
95,799
Greenhouse-Geisser
3065,571
26,723
114,718
Huynh-Feldt
3065,571
29,469
104,027
Lower-bound
3065,571
16,000
191,598
df
F
15,250
15,250
15,250
15,250
Sig.
,000
,000
,000
,001
Tests of Within-Subjects Contrasts
Measure: MEASURE_1
Source
KalsiumxFosfat
Error(KalsiumxFosfat)
KalsiumxFosfat
Linear
Quadratic
Linear
Quadratic
Type III Sum of
Squares
2907,275
14,653
2057,088
df
1008,483
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
df
Mean Square
Intercept
244165,283
1
244165,283
Error
9144,786
16
571,549
F
427,199
1
1
16
Mean Square
2907,275
14,653
128,568
16
63,030
Sig.
,000
Universitas Sumatera Utara
F
22,613
,232
Sig
71
Estimated Marginal Means
KalsiumxFosfat
Estimates
Measure: MEASURE_1
KalsiumxFosfat
1
2
3
Mean
78,818
68,434
60,324
Std. Error
3,339
3,551
4,597
95% Confidence Interval
Lower Bound
Upper Bound
71,739
85,897
60,906
75,962
50,580
70,069
Pairwise Comparisons
Measure: MEASURE_1
(I)
Kalsium
xFosfat
1
Mean Difference
(J) KalsiumxFosfat
(I-J)
Std. Error
*
2
10,384
3,480
3
18,494*
3,889
2
1
-10,384*
3,480
3
8,110*
2,564
3
1
-18,494*
3,889
2
-8,110*
2,564
Based on estimated marginal means
*. The mean difference is significant at the ,05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Sig.b
,026
,001
,026
,018
,001
,018
95% Confidence Interval for
Differenceb
Lower Bound
Upper Bound
1,081
19,687
8,098
28,890
-19,687
-1,081
1,256
14,964
-28,890
-8,098
-14,964
-1,256
Multivariate Tests
Value
F
Hypothesis df
Error df
Sig.
Pillai's trace
,596
11,069a
2,000
15,000
,001
Wilks' lambda
,404
11,069a
2,000
15,000
,001
Hotelling's trace
1,476
11,069a
2,000
15,000
,001
Roy's largest root
1,476
11,069a
2,000
15,000
,001
Each F tests the multivariate effect of KalsiumxFosfat. These tests are based on the linearly
independent pairwise comparisons among the estimated marginal means.
a. Exact statistic
Friedman Test
Ranks
Trombosit sebelum pemberian Niacinamide, mg/dl
Trombosit setelah pemberian Niacinamide 4 minggu, mg/dl
Trombosit setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
1,91
1,94
2,15
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
,567
2
,753
Universitas Sumatera Utara
72
Friedman Test
Ranks
SGOT sebelum pemberian Niacinamide, mg/dl
SGOT setelah pemberian Niacinamide 4 minggu, mg/dl
SGOT setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
2,32
2,03
1,65
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
4,290
2
,117
Friedman Test
Ranks
SGPT sebelum pemberian Niacinamide, mg/dl
SGPT setelah pemberian Niacinamide 4 minggu, mg/dl
SGPT setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
2,06
2,29
1,65
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
3,815
2
,148
Friedman Test
Ranks
HDL sebelum pemberian Niacinamide, mg/dl
HDL setelah pemberian Niacinamide 4 minggu, mg/dl
HDL setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
2,00
1,88
2,12
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
,492
2
,782
Universitas Sumatera Utara
73
General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
LDL
Dependent Variable
1
LDL1
2
LDL2
3
LDL3
Multivariate Testsa
Value
F
Hypothesis df
,062
,492b
2,000
,938
,492b
2,000
,066
,492b
2,000
,066
,492b
2,000
Effect
LDL
Pillai's Trace
Wilks' Lambda
Hotelling's Trace
Roy's Largest Root
a. Design: Intercept
Within Subjects Design: LDL
b. Exact statistic
Error df
15,000
15,000
15,000
15,000
Sig.
,621
,621
,621
,621
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Epsilonb
Within Subjects
Approx. ChiGreenhouseEffect
Mauchly's W
Square
df Sig.
Geisser
Huynh-Feldt
Lower-bound
LDL
,976
,360
2 ,835
,977
1,000
,500
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
a. Design: Intercept
Within Subjects Design: LDL
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed
in the Tests of Within-Subjects Effects table.
Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
LDL
Error(LDL)
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Type III Sum of
Squares
143,569
143,569
143,569
143,569
4547,765
Greenhouse-Geisser
df
2
1,954
2,000
1,000
32
Mean Square
71,784
73,486
71,784
143,569
142,118
4547,765
31,259
145,486
Huynh-Feldt
4547,765
32,000
142,118
Lower-bound
4547,765
16,000
284,235
F
,505
,505
,505
,505
Tests of Within-Subjects Contrasts
Measure: MEASURE_1
Source
LDL
Error(LDL)
LDL
Linear
Quadratic
Linear
Type III Sum of
Squares
,029
143,539
2296,471
Quadratic
2251,294
df
1
1
16
Mean Square
,029
143,539
143,529
16
140,706
F
,000
1,020
Sig.
,989
,328
Universitas Sumatera Utara
Sig.
,608
,604
,608
,487
74
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
df
Mean Square
Intercept
502428,314
1
502428,314
Error
23740,353
16
1483,772
F
338,616
Sig.
,000
Estimated Marginal Means
LDL
Estimates
Measure: MEASURE_1
LDL
1
2
3
Mean
100,412
96,882
100,471
Std. Error
6,035
5,356
6,236
95% Confidence Interval
Lower Bound
Upper Bound
87,617
113,206
85,529
108,236
87,250
113,691
Pairwise Comparisons
Measure: MEASURE_1
Mean Difference
(I) LDL
(J) LDL
(I-J)
Std. Error
1
2
3,529
4,343
3
-,059
4,109
2
1
-3,529
4,343
3
-3,588
3,796
3
1
,059
4,109
2
3,588
3,796
Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.
Sig.a
1,000
1,000
1,000
1,000
1,000
1,000
95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-8,079
15,138
-11,043
10,925
-15,138
8,079
-13,736
6,560
-10,925
11,043
-6,560
13,736
Multivariate Tests
Value
F
Hypothesis df
Error df
Sig.
a
Pillai's trace
,062
,492
2,000
15,000
,621
a
Wilks' lambda
,938
,492
2,000
15,000
,621
Hotelling's trace
,066
,492a
2,000
15,000
,621
Roy's largest root
,066
,492a
2,000
15,000
,621
Each F tests the multivariate effect of LDL. These tests are based on the linearly independent
pairwise comparisons among the estimated marginal means.
a. Exact statistic
Universitas Sumatera Utara
75
LAMPIRAN 7
DAFTAR RIWAYAT HIDUP
I.
Identitas Pribadi
Nama
Tempat/Tgl Lahir
Suku/Bangsa
Agama
Alamat
II. Keluarga
Suami
Anak
: dr. Meivina Ramadhani Pane
: Medan / 15 Mei 1986
: Mandailing / Indonesia
: Islam
: Jl. Suka Ramai No.4 Medan
: Lettu CKM dr. Esra Julianda Bangun
: Rafif Ravi Ahza Bangun
III. Pendidikan
SD Taman Harapan, Medan
SLTP Sutomo 1, Medan
SMU Sutomo 1, Medan
Fakultas Keddokteran USU
Tamat Tahun 1997
Tamat Tahun 2000
Tamat Tahun 2003
Tamat Tahun 2008
IV. Riwayat Pekerjaan
Dokter jaga RSU Bina kasih Medan tahun 2009
V. Perkumpulan Profesi
IDI Medan
PAPDI Sumut
VI. Journal Reading:
1. Pandit S, Chaudhuri AD, Datta SBS, Dey A, Bhanja P. Role of
pleural biopsy in etiological diagnosis of pleural effusion. Lung
India J. 2010;27:202-204
2. Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary
phosphate restriction & survival among hemodialysis patients. Clin
J Am Soc Nephrol. 2011;6:620-629
3. Mitwalli AH, Alam AA, Wakeel JS, Isnani AC. Dyslipidemia in
dialysis patients. Saudi J Kidney Dis Transpl 2011;22:689-694
Universitas Sumatera Utara
76
4. De-Madaria E, Soler-Sala G, Lopez-font I, et al. Influence of fluid
therapy on the prognosis of the acute pancreatitis: a prospective
cohort study. Am J Gastroenterol. 2011;106:1843-1850
5. Zirpoli JC, Lacerda HR, Albuquerqu VMG, et al. Angina pectoris in
patients with HIV/AIDS: prevalence & risk factors. Braz J Infect
Dis. 2012;16:1-8
6. Kabadi SM, Lee BK, Liu L. Joint effects of obesity and vit D
insufficiency on insulin resistance and type 2 diabetes. Diabetes
Journal. 2012;1-6
7. Al-Amran FG, Zwain AMH, Al-Mudhaffer AM. Autonomic cerebral
vascular respone to sildenafil in diabetic patient. Diabetology &
Metabolic syndrome. 2012;4:1-7
8. Herzig K, Purhonen A, Rasanen KM, Idziak J, Juvonen P, Phillps
R, Walkowiak J. Fecal elastase-1 levels in older individuals without
known gastrointestinal diseases or diabetes melitus. BMC
geriatrics. 2011;11:1-5
9. Xiaoshan S, Hongyun L. Anticoagulan therapy in patients with
COPD in the acute exacerbation stage. 2013;5(5):1367-1370
10. Fujiyoshi A, Murad MH, Luna M, Rosario A, Ali S, Paniagua D et
al. Metabolic syndrome & its components are underdiagnosed in
cardiology clinic. J Eval Clin Pract. 2011;17(1):78-83
VII. Tulisan Ilmiah
1. Pemberian kembali OAT pada penderita hepatitis imbas obat
akibat OAT.
2. Nefritis Lupus: klinis & diagnosis.
3. Akut miokard infark dengan elevasi segmen ST.
4. Penatalaksanaan kanker gaster.
5. Koinfeksi hepatitis C pada pasien HIV/AIDS.
6. Vitamin D dan kardiovaskular.
7. Depresi pada usia lanjut.
8. Kandung kemih hiperaktif pada usia lanjut.
9. Heparin induced trombocytopenia.
10. Artritis Septik
Universitas Sumatera Utara
77
VIII.
Publikasi Ilmiah
1. Pane MR, Sembiring E, Marpaung S, Ginting F, Kembaren T,
Rahimi A, Ginting J. Analisis survival 24 bulan pada pasien
HIV/AIDS yang mendapatkan ARV berdasarkan CD4 awal di RS.
Haji Adam Malik Medan. Kongres Nasional PETRI XVIII, Banda
Aceh, 2012
2. Pane MR, Susilo T, Safri Z, Lubis AR. Pengaruh terapi
hemodialisis reguler terhadap kejadian hipertensi pulmonal.
Annual Meeting of Nephrology PERNEFRI, Bali, 2012.
Universitas Sumatera Utara
LAMPIRAN 1
Universitas Sumatera Utara
52
LAMPIRAN 2
LEMBARAN PENJELASAN
Assalamualaikum wr.wb,
Salam sejahtera bagi Bapak/Ibu,
Terima kasih atas kesediaan Bapak/Ibu meluangkan waktu untuk
membaca dan mengisi surat persetujuan ini, sebelumnya, perkenankan saya
memperkenalkan diri. Nama saya dr. Meivina Ramadhani Pane, Peserta Program
Pendidikan Dokter Spesialis Ilmu Penyakit Dalam di Fakultas Kedokteran
Universitas Sumatera Utara (FK-USU). Saya sedang melakukan pengumpulan
data penelitian tugas akhir sebagai salah satu syarat menyelesaikan pendidikan di
FK-USU. Adapun judul penelitian saya adalah ―Efikasi dan keamanan
nikotinamide dalam penanganan hiperfosfatemia pada pasien hemodialisis‖
Penelitian ini bertujuan untuk mengetahui efektivitas dan keamanan
penggunaan Nikotinamide dalam menurunkan kadar fosfat darah pada pasien cuci
darah dengan harga yang relatif lebih murah dibandingkan dengan obat yang
sudah ada sebelumnya di pasaran.
Penelitian ini dimulai dengan pengambilan sampel darah vena sebanyak ±
2 sendok makan yang dilakukan sebelum hemodialisis dimulai. Sampel darah ini
digunakan untuk pemeriksaan darah rutin, LFT, RFT, fosfat, kalsium, albumin,
dan profil lipid. Kemudian apabila kadar serum fosfat pasien ≥ 5.5 mg/dl, maka
akan diberikan kapsul nikotinamide 250 mg 2 kali sehari pada pagi dan petang
hari pada saat makan. Kemudian setelah 4 minggu dan 8 minggu dilakukan
pengambilan darah kembali untuk menilai darah rutin, fosfat, kalsium, fungsi hati,
fungsi ginjal dan profil lipid.
Universitas Sumatera Utara
53
Penelitian ini tidak berbahaya, pada saat pengambilan darah dapat timbul
lebam pada bekas tempat pengambilan yang akan hilang sendiri dalam satu atau
dua hari. Sementara nikotinamide berdasarkan pengalaman selama ini belum
pernah menunjukkan bahaya yang serius. Beberapa efek samping yang mungkin
terjadi dari pemberian obat ini adalah diare, penurunan kadar trombosit dan
kemerahan pada wajah. Namun efek samping tersebut akan hilang jika dosis obat
dikurangi. Efek samping obat tersebut biasanya terjadi jika diberikan dengan dosis
tinggi, sedangkan pada penelitian ini dosis obat yang diberikan adalah 500 mg per
hari. Segala biaya pemeriksaan laboratorium, penyediaan obat dan biaya
penanganan yang diperlukan bila timbul efek samping akan menjadi tanggung
jawab peneliti.
Terimakasih atas keikutsertaan Bapak/Ibu. Apabila ada hal-hal yang
terjadi selama penelitian dan ada keterangan yang saya berikan masih belum jelas
atau yang ingin ditanyakan, Bapak/Ibu dapat menghubungi saya :
Nama
: dr. Meivina Ramadhani Pane
Alamat
: Jl. Suka Ramai No.4 Medan
No Telp
: 081260297727
Atas perhatian Bapak/Ibu saya ucapkan terima kasih.
Hormat saya,
dr. Meivina Ramadhani Pane
Universitas Sumatera Utara
54
LAMPIRAN 3
LEMBAR PERSETUJUAN SETELAH PENJELASAN
(INFORMED CONSENT)
=======================================================
No. Peserta :
Saya yang bertanda tangan di bawah ini :
Nama
:
Umur
:
Jenis Kelamin
: Laki-laki / Perempuan *
Alamat
:
No. Telepon
:
tahun
Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan
prosedur penelitian ini, menyatakan bersedia untuk ikut dalam penelitian tentang :
―EFIKASI DAN KEAMANAN NIKOTINAMIDE DALAM PENANGANAN
HIPERFOSFATEMIA PADA PASIEN HEMODIALISIS‖.
Demikian surat pernyataan bersedia ikut dalam penelitian ini saya perbuat
untuk dapat digunakan seperlunya.
Medan,
2013
Peneliti,
Pasien,
( dr. Meivina Ramadhani Pane )
(.......................................)
Saksi,
(................................)
Universitas Sumatera Utara
55
LAMPIRAN 4
KERTAS KERJA PROFIL PESERTA PENELITIAN
I. IDENTITAS PRIBADI
Nama
:
Umur
:
Jenis Kelamin
: pria/wanita
Riwayat penyakit
: DM/hipertensi/batu ginjal/kista
HD sejak
:
tahun
II. HASIL PEMERIKSAAN LABORATORIUM
Parameter
Sebelum
Minggu ke-4
Minggu Ke-8
Fosfat (mg/dl)
Kalsium (mg/dl)
Fosfat x kalsium
(mg2/dl2)
Trombosit (x103/mm3)
SGOT (U/L)
SGPT (U/L)
HDL (mg/dl)
LDL (mg/dl)
III. EFEK SAMPING YANG TIMBUL (sebutkan)
.................................
Universitas Sumatera Utara
56
LAMPIRAN 5
Data Penelitian Sebelum Pemberian Nikotinamide
Pasien
Umur
(THN)
JK
Fosfat
(mg/dl)
Kalsium
(mg/dl)
CaxP
(mg2/dl2)
Trombosit
(103/mm3)
SGOT
(U/L)
SGPT
(U/L)
HDL
(mg/dl)
LDL
(mg/dl)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
54
55
38
70
40
53
43
46
41
59
43
35
38
44
42
32
54
P
P
L
L
L
L
L
L
L
L
L
L
L
L
P
L
P
7
7
7.2
6.3
7.9
6.3
11.3
8.1
9.2
9.5
9.5
9
7.3
9.9
7.4
9.5
6.2
9.2
10.3
8.6
9.8
9.1
9.9
9
9.6
10.3
9.6
10.3
10
10.6
9.1
8.8
9.3
11.5
64.4
72.1
61.9
61.74
71.89
62.37
101.7
77.76
94.76
91.2
97.85
90
77.38
90.09
65.12
88.35
71.3
179
186
147
160
340
157
130
123
213
284
331
173
263
167
230
165
237
23
31
45
51
23
34
20
18
65
71
16
34
19
18
31
37
41
22
45
16
37
15
49
50
13
11
45
10
43
14
17
29
48
51
43
38
33
35
23
34
37
38
33
50
49
37
64
56
54
28
49
131
83
64
101
123
99
60
138
113
99
99
78
143
110
109
88
69
Data Penelitian Setelah Minggu ke-4 Pemberian Nikotinamide
Pasien
Umur
(THN)
JK
Fosfat
(mg/dl)
Kalsium
(mg/dl)
CaxP
(mg2/dl2)
Trombosit
(103/mm3)
SGOT
(U/L)
SGPT
(U/L)
HDL
(mg/dl)
LDL
(mg/dl)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
54
55
38
70
40
53
43
46
41
59
43
35
38
44
42
32
54
P
P
L
L
L
L
L
L
L
L
L
L
L
L
P
L
P
9.7
8
5.5
5.7
8
5.7
10.6
7.6
8.3
6.6
8.1
5.6
7
10.2
6.5
9.3
5.8
8.6
10.6
8.7
9.8
8.4
8.2
7.5
8.8
10
9
10.2
8.6
10.7
8.9
8.3
8.2
10.7
83.42
84.8
47.85
55.86
67.2
46.74
79.5
66.88
83
59.4
82.62
48.16
74.9
90.78
53.95
76.26
62.06
146
221
172
165
228
166
125
129
198
246
243
170
283
195
200
282
215
28
23
23
38
22
18
44
12
20
33
20
35
19
17
32
45
27
20
41
40
35
25
30
63
22
17
35
13
44
13
17
35
55
23
41
41
34
37
27
25
44
35
38
44
35
38
53
56
20
38
27
123
68
77
98
149
105
63
112
116
110
70
81
98
104
97
90
86
Universitas Sumatera Utara
57
Data Penelitian Setelah Minggu ke-8 Pemberian Nikotinamide
Pasien
Umur
(THN)
JK
Fosfat
(mg/dl)
Kalsium
(mg/dl)
CaxP
(mg2/dl2)
Trombosit
(103/mm3)
SGOT
(U/L)
SGPT
(U/L)
HDL
(mg/dl)
LDL
(mg/dl)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
54
55
38
70
40
53
43
46
41
59
43
35
38
44
42
32
54
P
P
L
L
L
L
L
L
L
L
L
L
L
L
P
L
P
7.8
7.9
5.2
3.4
6.9
5.1
9.6
5.3
7.2
5.1
8.5
5.5
7.9
9.9
6.3
9.1
2.7
8.2
10.9
8.8
9.6
8.7
8.5
8.8
8.6
10
8.7
9.7
8.3
10
8.2
8.5
9.1
11.7
63.96
86.11
45.76
32.64
60.03
43.35
84.48
45.58
72
44.37
82.45
45.65
70
81.18
53.55
82.81
31.59
258
251
165
160
348
170
167
159
189
230
252
161
287
158
232
249
155
34
21
22
28
20
20
12
13
16
30
18
34
19
27
32
23
35
23
31
35
21
23
28
19
20
10
40
10
37
13
55
33
29
27
41
39
35
41
30
30
42
40
45
48
30
37
37
76
39
26
35
120
64
78
95
139
97
76
125
110
125
75
75
124
103
146
79
77
Keterangan:
P : Perempuan
L : Laki-laki
Universitas Sumatera Utara
58
LAMPIRAN 6
OUTPUT ANALISIS
Jk
Valid
L
P
Total
Frequency
13
4
Percent
76,5
23,5
Valid Percent
76,5
23,5
17
100,0
100,0
Cumulative
Percent
76,5
100,0
Penyebab
Valid
Batu ginjal
DM
DN
GNC
HN
Total
Umur
Lama HD (tahun)
Ca1
Ca2
Ca3
Fosfat1
Fosfat2
Fosfat3
CaxFosfat1
CaxFosfat2
CaxFosfat3
Trombosit1
Trombosit2
Trombosit3
SGOT1
SGOT2
SGOT3
SGPT1
SGPT2
SGPT3
HDL1
HDL2
HDL3
LDL1
LDL2
LDL3
Frequency
1
1
3
1
11
Percent
5,9
5,9
17,6
5,9
64,7
Valid Percent
5,9
5,9
17,6
5,9
64,7
17
100,0
100,0
Cumulative
Percent
5,9
11,8
29,4
35,3
100,0
Case Processing Summary
Cases
Valid
Missing
N
Percent
N
Percent
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
17
100,0%
0
0,0%
Total
N
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
Percent
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
100,0%
Universitas Sumatera Utara
59
Descriptives
Umur
Mean
95% Confidence Interval for
Mean
Statistic
46,2941
Lower Bound
41,2409
Upper Bound
51,3474
5% Trimmed Mean
45,7712
Median
43,0000
Variance
96,596
Std. Deviation
Lama HD (tahun)
9,82831
Minimum
32,00
Maximum
70,00
Range
38,00
Interquartile Range
15,00
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
,835
,512
4,2453
2,9773
Upper Bound
5,5133
5% Trimmed Mean
4,1798
Median
4,0000
Variance
2,46622
Minimum
,67
Maximum
9,00
Range
8,33
Interquartile Range
Ca1
Lower Bound
4,25
,448
-,760
9,7059
9,3218
Upper Bound
10,0900
5% Trimmed Mean
9,6676
Median
9,6000
Variance
,74705
Minimum
8,60
Maximum
11,50
Range
2,90
Interquartile Range
Ca2
,550
1,063
,18119
,558
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
,59815
6,082
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Std. Error
2,38371
Lower Bound
1,20
,690
,484
9,1294
8,6157
Upper Bound
9,6432
5% Trimmed Mean
9,1327
Median
8,8000
,550
1,063
,24235
Universitas Sumatera Utara
60
Variance
,998
Std. Deviation
,99923
Minimum
7,50
Maximum
10,70
Range
3,20
Interquartile Range
Ca3
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
1,75
,412
-1,059
9,1941
8,6830
Upper Bound
9,7052
5% Trimmed Mean
9,1101
Median
8,8000
Variance
,988
Std. Deviation
,99403
Minimum
8,20
Maximum
11,70
Range
3,50
Interquartile Range
Fosfat1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
1,35
1,300
1,211
8,1529
7,3836
Upper Bound
8,9223
5% Trimmed Mean
8,0866
Median
7,9000
Variance
1,49629
Minimum
6,20
Maximum
11,30
Range
5,10
Interquartile Range
Fosfat2
Lower Bound
2,50
,432
-,708
7,5412
6,6741
Upper Bound
8,4082
5% Trimmed Mean
7,4846
Median
7,6000
Variance
1,68636
Minimum
5,50
Maximum
10,60
Range
5,10
Interquartile Range
Fosfat3
,550
1,063
,40900
2,844
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
,550
1,063
,36290
2,239
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
,24109
Lower Bound
3,05
,414
-1,010
6,6706
5,5964
,550
1,063
,50670
Universitas Sumatera Utara
61
Mean
Upper Bound
6,7118
Median
6,9000
Variance
4,365
Std. Deviation
2,08919
Minimum
2,70
Maximum
9,90
Range
7,20
Interquartile Range
CaxFosfat1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
3,05
-,219
-,693
78,8182
71,7393
Upper Bound
85,8972
5% Trimmed Mean
78,4958
Median
77,3800
Variance
13,76813
Minimum
61,74
Maximum
101,70
Range
39,96
Interquartile Range
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
25,89
,207
-1,479
68,4341
60,9060
Upper Bound
75,9622
5% Trimmed Mean
68,3979
Median
67,2000
Variance
214,383
Std. Deviation
46,74
Maximum
90,78
Range
44,04
Interquartile Range
CaxFosfat3
Lower Bound
27,91
-,143
-1,428
60,3241
50,5796
Upper Bound
70,0687
5% Trimmed Mean
60,4879
Median
60,0300
Variance
Std. Deviation
,550
1,063
3,55116
14,64183
Minimum
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
3,33926
189,561
Std. Deviation
CaxFosfat2
7,7447
5% Trimmed Mean
,550
1,063
4,59669
359,203
18,95265
Minimum
31,59
Maximum
86,11
Range
54,52
Interquartile Range
36,84
Universitas Sumatera Utara
62
Trombosit1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
,015
-1,503
205,00
170,85
Upper Bound
239,15
5% Trimmed Mean
202,06
Median
179,00
Variance
4410,375
Std. Deviation
66,411
Minimum
123
Maximum
340
Range
217
Interquartile Range
Trombosit2
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
92
,883
-,194
199,06
174,44
Upper Bound
223,68
5% Trimmed Mean
198,51
Median
198,00
Variance
47,886
Minimum
125
Maximum
283
Range
158
Interquartile Range
Trombosit3
Lower Bound
70
,238
-,670
211,24
181,85
Upper Bound
240,62
5% Trimmed Mean
189,00
Variance
3265,441
Std. Deviation
57,144
Minimum
155
Maximum
348
Range
193
Interquartile Range
SGOT1
Lower Bound
91
,872
,148
33,94
25,50
Upper Bound
42,38
5% Trimmed Mean
32,88
Median
31,00
Variance
Std. Deviation
Minimum
,550
1,063
13,859
206,76
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
11,614
2293,059
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
16,107
,550
1,063
3,983
269,684
16,422
16
Universitas Sumatera Utara
63
Maximum
71
Range
55
Interquartile Range
SGOT2
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
24
1,039
,435
26,82
21,87
Upper Bound
31,78
5% Trimmed Mean
26,64
Median
23,00
Variance
92,779
Std. Deviation
9,632
Minimum
12
Maximum
45
Range
33
Interquartile Range
SGOT3
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
15
,568
-,577
23,76
19,95
Upper Bound
27,58
5% Trimmed Mean
23,79
Median
22,00
Variance
7,421
Minimum
12
Maximum
35
Range
23
Interquartile Range
SGPT1
Lower Bound
13
,121
-1,172
30,29
22,01
Upper Bound
38,58
5% Trimmed Mean
29,00
Variance
259,596
Std. Deviation
16,112
Minimum
10
Maximum
51
Range
41
Interquartile Range
SGPT2
,550
1,063
3,908
30,27
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
1,800
55,066
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
2,336
Lower Bound
32
,049
-1,931
31,06
23,63
Upper Bound
38,49
5% Trimmed Mean
30,29
Median
30,00
,550
1,063
3,505
Universitas Sumatera Utara
64
Variance
208,809
Std. Deviation
14,450
Minimum
13
Maximum
63
Range
50
Interquartile Range
SGPT3
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
22
,708
-,039
26,71
20,78
Upper Bound
32,63
5% Trimmed Mean
26,06
Median
27,00
Variance
132,971
Std. Deviation
11,531
Minimum
10
Maximum
55
Range
45
Interquartile Range
HDL1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
15
,649
,917
41,24
35,65
Upper Bound
46,82
5% Trimmed Mean
38,00
Variance
118,191
Std. Deviation
10,872
Minimum
23
Maximum
64
Range
41
Interquartile Range
HDL2
Lower Bound
16
,461
-,323
37,24
32,43
Upper Bound
42,04
5% Trimmed Mean
37,15
Median
38,00
Variance
9,351
Minimum
20
Maximum
56
Range
36
Interquartile Range
HDL3
,550
1,063
2,268
87,441
Std. Deviation
Skewness
Kurtosis
Mean
95% Confidence Interval for
,550
1,063
2,637
40,98
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
2,797
Lower Bound
12
,182
,191
39,47
33,79
,550
1,063
2,679
Universitas Sumatera Utara
65
Mean
Upper Bound
38,19
Median
39,00
Variance
122,015
Std. Deviation
11,046
Minimum
26
Maximum
76
Range
50
Interquartile Range
LDL1
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
9
2,331
7,628
100,41
87,62
Upper Bound
113,21
5% Trimmed Mean
99,00
Variance
619,257
Std. Deviation
24,885
Minimum
60
Maximum
143
Range
83
Interquartile Range
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
Lower Bound
38
,047
-,753
96,88
85,53
Upper Bound
108,24
5% Trimmed Mean
98,00
Variance
487,610
Std. Deviation
22,082
Minimum
63
Maximum
149
Range
86
Interquartile Range
LDL3
32
,507
,494
100,47
Lower Bound
87,25
Upper Bound
113,69
5% Trimmed Mean
99,97
Median
97,00
Variance
Std. Deviation
,550
1,063
6,236
661,140
25,713
Minimum
64
Maximum
146
Range
,550
1,063
5,356
95,87
Median
Skewness
Kurtosis
Mean
95% Confidence Interval for
Mean
,550
1,063
6,035
100,29
Median
LDL2
45,15
5% Trimmed Mean
82
Universitas Sumatera Utara
66
Interquartile Range
48
Skewness
Kurtosis
,299
-1,276
Tests of Normality
Kolmogorov-Smirnova
Statistic
df
Sig.
Umur
,181
17
,144
Lama HD (tahun)
,164
17
,200*
Ca1
,118
17
,200*
Ca2
,199
17
,073
Ca3
,242
17
,009
Fosfat1
,163
17
,200*
Fosfat2
,143
17
,200*
Fosfat3
,124
17
,200*
CaxFosfat1
,167
17
,200*
CaxFosfat2
,141
17
,200*
CaxFosfat3
,191
17
,101
Trombosit1
,201
17
,067
Trombosit2
,126
17
,200*
Trombosit3
,235
17
,013
SGOT1
,159
17
,200*
SGOT2
,184
17
,130
SGOT3
,129
17
,200*
SGPT1
,207
17
,051
SGPT2
,133
17
,200*
SGPT3
,097
17
,200*
HDL1
,205
17
,055
HDL2
,129
17
,200*
HDL3
,233
17
,015
LDL1
,124
17
,200*
LDL2
,090
17
,200*
LDL3
,210
17
,045
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Statistic
,935
,953
,955
,908
,856
,930
,919
,962
,907
,925
,905
,901
,962
,856
,888
,941
,941
,845
,937
,958
,958
,964
,771
,968
,969
,917
Shapiro-Wilk
df
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
,550
1,063
Sig.
,268
,503
,549
,091
,013
,220
,142
,674
,089
,179
,083
,072
,673
,013
,044
,335
,332
,009
,279
,600
,588
,715
,001
,787
,798
,131
Wilcoxon Signed Ranks Test
Ranks
N
Ca2 - Ca1
Ca3 - Ca1
Negative Ranks
Positive Ranks
Ties
13a
3b
Total
17
14d
3e
0f
Negative Ranks
Positive Ranks
Ties
Total
Ca3 - Ca2
Negative Ranks
Positive Ranks
Ties
Total
a. Ca2 < Ca1
b. Ca2 > Ca1
c. Ca2 = Ca1
d. Ca3 < Ca1
Mean Rank
9,73
3,17
Sum of Ranks
126,50
9,50
9,79
5,33
137,00
16,00
8,25
8,75
66,00
70,00
c
1
17
8g
8h
1i
17
e. Ca3 > Ca1
f. Ca3 = Ca1
g. Ca3 < Ca2
h. Ca3 > Ca2
Universitas Sumatera Utara
67
i. Ca3 = Ca2
Test Statistics
Ca2 - Ca1
Z
-3,029b
Asymp. Sig. (2-tailed)
,002
a. Wilcoxon Signed Ranks Test
b. Based on positive ranks.
c. Based on negative ranks.
a
Ca3 - Ca1
-2,875b
,004
Ca3 - Ca2
-,104c
,917
Friedman Test
Ranks
Mean Rank
Fosfat sebelum pemberian
Niacinamide, mg/dl
Fosfat setelah pemberian
Niacinamide 4 minggu,
mg/dl
Fosfat setelah pemberian
Niacinamide 8 minggu,
mg/dl
2,56
2,12
1,32
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
13,522
2
,001
General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
Fosfat
Dependent Variable
1
Fosfat1
2
Fosfat2
3
Fosfat3
a
Effect
Fosfat
Pillai's Trace
Wilks' Lambda
Hotelling's Trace
Roy's Largest Root
a. Design: Intercept
Within Subjects Design: Fosfat
b. Exact statistic
Multivariate Tests
Value
F
Hypothesis df
,521
8,142b
2,000
,479
8,142b
2,000
1,086
8,142b
2,000
1,086
8,142b
2,000
Error df
15,000
15,000
15,000
15,000
Sig.
,004
,004
,004
,004
Universitas Sumatera Utara
68
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Epsilonb
Within
Subjects
Approx. ChiGreenhouseEffect
Mauchly's W
Square
df Sig.
Geisser
Huynh-Feldt
Lower-bound
Fosfat
,814
3,093
2 ,213
,843
,931
,500
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent
variables is proportional to an identity matrix.
a. Design: Intercept
Within Subjects Design: Fosfat
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are
displayed in the Tests of Within-Subjects Effects table.
Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
Fosfat
Error(Fosfat)
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Type III Sum of
Squares
18,867
18,867
18,867
18,867
29,559
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
df
2
1,686
1,863
1,000
32
Mean Square
9,434
11,191
10,130
18,867
,924
29,559
26,974
1,096
29,559
29,800
,992
29,559
16,000
1,847
F
10,213
10,213
10,213
10,213
Tests of Within-Subjects Contrasts
Measure: MEASURE_1
Source
Fosfat
Error(Fosfat)
Fosfat
Linear
Quadratic
Linear
Type III Sum of
Squares
18,678
,190
20,132
Quadratic
9,427
df
1
1
16
Mean Square
18,678
,190
1,258
16
,589
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
Df
Mean Square
Intercept
2834,354
1
2834,354
Error
121,600
16
7,600
F
372,942
F
14,844
,322
Sig.
,001
,578
Sig.
,000
Universitas Sumatera Utara
Sig.
,00
,00
,00
,00
69
Estimated Marginal Means
Fosfat
Estimates
Measure: MEASURE_1
Fosfat
1
2
3
Mean
8,153
7,541
6,671
95% Confidence Interval
Lower Bound
Upper Bound
7,384
8,922
6,674
8,408
5,596
7,745
Std. Error
,363
,409
,507
Pairwise Comparisons
Measure: MEASURE_1
Mean Difference
(I) Fosfat
(J) Fosfat
(I-J)
Std. Error
1
2
,612
,333
3
1,482*
,385
2
1
-,612
,333
*
3
,871
,259
3
1
-1,482*
,385
*
2
-,871
,259
Based on estimated marginal means
*. The mean difference is significant at the ,05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Sig.b
,255
,004
,255
,012
,004
,012
95% Confidence Interval for
Differenceb
Lower Bound
Upper Bound
-,279
1,503
,454
2,511
-1,503
,279
,179
1,562
-2,511
-,454
-1,562
-,179
Multivariate Tests
Value
F
Hypothesis df
Error df
Pillai's trace
,521
8,142a
2,000
15,000
Wilks' lambda
,479
8,142a
2,000
15,000
Hotelling's trace
1,086
8,142a
2,000
15,000
Roy's largest root
1,086
8,142a
2,000
15,000
Each F tests the multivariate effect of Fosfat. These tests are based on the linearly
independent pairwise comparisons among the estimated marginal means.
a. Exact statistic
Sig.
,004
,004
,004
,004
General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
Dependent
KalsiumxFosfat
Variable
1
CaxFosfat1
2
CaxFosfat2
3
CaxFosfat3
Effect
KalsiumxFosfat
Pillai's Trace
Wilks' Lambda
Hotelling's Trace
Roy's Largest Root
Multivariate Testsa
Value
F
,596
11,069b
,404
11,069b
1,476
11,069b
1,476
11,069b
Hypothesis df
2,000
2,000
2,000
2,000
Error df
15,000
15,000
15,000
15,000
a. Design: Intercept
Within Subjects Design: KalsiumxFosfat
Universitas Sumatera Utara
Sig.
,001
,001
,001
,001
70
b. Exact statistic
Mauchly's Test of Sphericity
a
Measure: MEASURE_1
Epsilonb
Within Subjects
Approx. ChiGreenhouseEffect
Mauchly's W
Square
df Sig.
Geisser
Huynh-Feldt
Lower-bound
KalsiumxFosfat
,803
3,300
2 ,192
,835
,921
,500
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables
is proportional to an identity matrix.
a. Design: Intercept
Within Subjects Design: KalsiumxFosfat
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are
displayed in the Tests of Within-Subjects Effects table.
Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
KalsiumxFosfat
Error(KalsiumxFosfat)
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Type III Sum of
Squares
2921,928
2921,928
2921,928
2921,928
3065,571
2
1,670
1,842
1,000
32
Mean Square
1460,964
1749,487
1586,448
2921,928
95,799
Greenhouse-Geisser
3065,571
26,723
114,718
Huynh-Feldt
3065,571
29,469
104,027
Lower-bound
3065,571
16,000
191,598
df
F
15,250
15,250
15,250
15,250
Sig.
,000
,000
,000
,001
Tests of Within-Subjects Contrasts
Measure: MEASURE_1
Source
KalsiumxFosfat
Error(KalsiumxFosfat)
KalsiumxFosfat
Linear
Quadratic
Linear
Quadratic
Type III Sum of
Squares
2907,275
14,653
2057,088
df
1008,483
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
df
Mean Square
Intercept
244165,283
1
244165,283
Error
9144,786
16
571,549
F
427,199
1
1
16
Mean Square
2907,275
14,653
128,568
16
63,030
Sig.
,000
Universitas Sumatera Utara
F
22,613
,232
Sig
71
Estimated Marginal Means
KalsiumxFosfat
Estimates
Measure: MEASURE_1
KalsiumxFosfat
1
2
3
Mean
78,818
68,434
60,324
Std. Error
3,339
3,551
4,597
95% Confidence Interval
Lower Bound
Upper Bound
71,739
85,897
60,906
75,962
50,580
70,069
Pairwise Comparisons
Measure: MEASURE_1
(I)
Kalsium
xFosfat
1
Mean Difference
(J) KalsiumxFosfat
(I-J)
Std. Error
*
2
10,384
3,480
3
18,494*
3,889
2
1
-10,384*
3,480
3
8,110*
2,564
3
1
-18,494*
3,889
2
-8,110*
2,564
Based on estimated marginal means
*. The mean difference is significant at the ,05 level.
b. Adjustment for multiple comparisons: Bonferroni.
Sig.b
,026
,001
,026
,018
,001
,018
95% Confidence Interval for
Differenceb
Lower Bound
Upper Bound
1,081
19,687
8,098
28,890
-19,687
-1,081
1,256
14,964
-28,890
-8,098
-14,964
-1,256
Multivariate Tests
Value
F
Hypothesis df
Error df
Sig.
Pillai's trace
,596
11,069a
2,000
15,000
,001
Wilks' lambda
,404
11,069a
2,000
15,000
,001
Hotelling's trace
1,476
11,069a
2,000
15,000
,001
Roy's largest root
1,476
11,069a
2,000
15,000
,001
Each F tests the multivariate effect of KalsiumxFosfat. These tests are based on the linearly
independent pairwise comparisons among the estimated marginal means.
a. Exact statistic
Friedman Test
Ranks
Trombosit sebelum pemberian Niacinamide, mg/dl
Trombosit setelah pemberian Niacinamide 4 minggu, mg/dl
Trombosit setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
1,91
1,94
2,15
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
,567
2
,753
Universitas Sumatera Utara
72
Friedman Test
Ranks
SGOT sebelum pemberian Niacinamide, mg/dl
SGOT setelah pemberian Niacinamide 4 minggu, mg/dl
SGOT setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
2,32
2,03
1,65
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
4,290
2
,117
Friedman Test
Ranks
SGPT sebelum pemberian Niacinamide, mg/dl
SGPT setelah pemberian Niacinamide 4 minggu, mg/dl
SGPT setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
2,06
2,29
1,65
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
3,815
2
,148
Friedman Test
Ranks
HDL sebelum pemberian Niacinamide, mg/dl
HDL setelah pemberian Niacinamide 4 minggu, mg/dl
HDL setelah pemberian Niacinamide 8 minggu, mg/dl
Mean Rank
2,00
1,88
2,12
Test Statisticsa
N
Chi-Square
df
Asymp. Sig.
a. Friedman Test
17
,492
2
,782
Universitas Sumatera Utara
73
General Linear Model
Within-Subjects Factors
Measure: MEASURE_1
LDL
Dependent Variable
1
LDL1
2
LDL2
3
LDL3
Multivariate Testsa
Value
F
Hypothesis df
,062
,492b
2,000
,938
,492b
2,000
,066
,492b
2,000
,066
,492b
2,000
Effect
LDL
Pillai's Trace
Wilks' Lambda
Hotelling's Trace
Roy's Largest Root
a. Design: Intercept
Within Subjects Design: LDL
b. Exact statistic
Error df
15,000
15,000
15,000
15,000
Sig.
,621
,621
,621
,621
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Epsilonb
Within Subjects
Approx. ChiGreenhouseEffect
Mauchly's W
Square
df Sig.
Geisser
Huynh-Feldt
Lower-bound
LDL
,976
,360
2 ,835
,977
1,000
,500
Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is
proportional to an identity matrix.
a. Design: Intercept
Within Subjects Design: LDL
b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed
in the Tests of Within-Subjects Effects table.
Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
LDL
Error(LDL)
Sphericity Assumed
Greenhouse-Geisser
Huynh-Feldt
Lower-bound
Sphericity Assumed
Type III Sum of
Squares
143,569
143,569
143,569
143,569
4547,765
Greenhouse-Geisser
df
2
1,954
2,000
1,000
32
Mean Square
71,784
73,486
71,784
143,569
142,118
4547,765
31,259
145,486
Huynh-Feldt
4547,765
32,000
142,118
Lower-bound
4547,765
16,000
284,235
F
,505
,505
,505
,505
Tests of Within-Subjects Contrasts
Measure: MEASURE_1
Source
LDL
Error(LDL)
LDL
Linear
Quadratic
Linear
Type III Sum of
Squares
,029
143,539
2296,471
Quadratic
2251,294
df
1
1
16
Mean Square
,029
143,539
143,529
16
140,706
F
,000
1,020
Sig.
,989
,328
Universitas Sumatera Utara
Sig.
,608
,604
,608
,487
74
Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
df
Mean Square
Intercept
502428,314
1
502428,314
Error
23740,353
16
1483,772
F
338,616
Sig.
,000
Estimated Marginal Means
LDL
Estimates
Measure: MEASURE_1
LDL
1
2
3
Mean
100,412
96,882
100,471
Std. Error
6,035
5,356
6,236
95% Confidence Interval
Lower Bound
Upper Bound
87,617
113,206
85,529
108,236
87,250
113,691
Pairwise Comparisons
Measure: MEASURE_1
Mean Difference
(I) LDL
(J) LDL
(I-J)
Std. Error
1
2
3,529
4,343
3
-,059
4,109
2
1
-3,529
4,343
3
-3,588
3,796
3
1
,059
4,109
2
3,588
3,796
Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.
Sig.a
1,000
1,000
1,000
1,000
1,000
1,000
95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-8,079
15,138
-11,043
10,925
-15,138
8,079
-13,736
6,560
-10,925
11,043
-6,560
13,736
Multivariate Tests
Value
F
Hypothesis df
Error df
Sig.
a
Pillai's trace
,062
,492
2,000
15,000
,621
a
Wilks' lambda
,938
,492
2,000
15,000
,621
Hotelling's trace
,066
,492a
2,000
15,000
,621
Roy's largest root
,066
,492a
2,000
15,000
,621
Each F tests the multivariate effect of LDL. These tests are based on the linearly independent
pairwise comparisons among the estimated marginal means.
a. Exact statistic
Universitas Sumatera Utara
75
LAMPIRAN 7
DAFTAR RIWAYAT HIDUP
I.
Identitas Pribadi
Nama
Tempat/Tgl Lahir
Suku/Bangsa
Agama
Alamat
II. Keluarga
Suami
Anak
: dr. Meivina Ramadhani Pane
: Medan / 15 Mei 1986
: Mandailing / Indonesia
: Islam
: Jl. Suka Ramai No.4 Medan
: Lettu CKM dr. Esra Julianda Bangun
: Rafif Ravi Ahza Bangun
III. Pendidikan
SD Taman Harapan, Medan
SLTP Sutomo 1, Medan
SMU Sutomo 1, Medan
Fakultas Keddokteran USU
Tamat Tahun 1997
Tamat Tahun 2000
Tamat Tahun 2003
Tamat Tahun 2008
IV. Riwayat Pekerjaan
Dokter jaga RSU Bina kasih Medan tahun 2009
V. Perkumpulan Profesi
IDI Medan
PAPDI Sumut
VI. Journal Reading:
1. Pandit S, Chaudhuri AD, Datta SBS, Dey A, Bhanja P. Role of
pleural biopsy in etiological diagnosis of pleural effusion. Lung
India J. 2010;27:202-204
2. Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary
phosphate restriction & survival among hemodialysis patients. Clin
J Am Soc Nephrol. 2011;6:620-629
3. Mitwalli AH, Alam AA, Wakeel JS, Isnani AC. Dyslipidemia in
dialysis patients. Saudi J Kidney Dis Transpl 2011;22:689-694
Universitas Sumatera Utara
76
4. De-Madaria E, Soler-Sala G, Lopez-font I, et al. Influence of fluid
therapy on the prognosis of the acute pancreatitis: a prospective
cohort study. Am J Gastroenterol. 2011;106:1843-1850
5. Zirpoli JC, Lacerda HR, Albuquerqu VMG, et al. Angina pectoris in
patients with HIV/AIDS: prevalence & risk factors. Braz J Infect
Dis. 2012;16:1-8
6. Kabadi SM, Lee BK, Liu L. Joint effects of obesity and vit D
insufficiency on insulin resistance and type 2 diabetes. Diabetes
Journal. 2012;1-6
7. Al-Amran FG, Zwain AMH, Al-Mudhaffer AM. Autonomic cerebral
vascular respone to sildenafil in diabetic patient. Diabetology &
Metabolic syndrome. 2012;4:1-7
8. Herzig K, Purhonen A, Rasanen KM, Idziak J, Juvonen P, Phillps
R, Walkowiak J. Fecal elastase-1 levels in older individuals without
known gastrointestinal diseases or diabetes melitus. BMC
geriatrics. 2011;11:1-5
9. Xiaoshan S, Hongyun L. Anticoagulan therapy in patients with
COPD in the acute exacerbation stage. 2013;5(5):1367-1370
10. Fujiyoshi A, Murad MH, Luna M, Rosario A, Ali S, Paniagua D et
al. Metabolic syndrome & its components are underdiagnosed in
cardiology clinic. J Eval Clin Pract. 2011;17(1):78-83
VII. Tulisan Ilmiah
1. Pemberian kembali OAT pada penderita hepatitis imbas obat
akibat OAT.
2. Nefritis Lupus: klinis & diagnosis.
3. Akut miokard infark dengan elevasi segmen ST.
4. Penatalaksanaan kanker gaster.
5. Koinfeksi hepatitis C pada pasien HIV/AIDS.
6. Vitamin D dan kardiovaskular.
7. Depresi pada usia lanjut.
8. Kandung kemih hiperaktif pada usia lanjut.
9. Heparin induced trombocytopenia.
10. Artritis Septik
Universitas Sumatera Utara
77
VIII.
Publikasi Ilmiah
1. Pane MR, Sembiring E, Marpaung S, Ginting F, Kembaren T,
Rahimi A, Ginting J. Analisis survival 24 bulan pada pasien
HIV/AIDS yang mendapatkan ARV berdasarkan CD4 awal di RS.
Haji Adam Malik Medan. Kongres Nasional PETRI XVIII, Banda
Aceh, 2012
2. Pane MR, Susilo T, Safri Z, Lubis AR. Pengaruh terapi
hemodialisis reguler terhadap kejadian hipertensi pulmonal.
Annual Meeting of Nephrology PERNEFRI, Bali, 2012.
Universitas Sumatera Utara